← Back

Virion Biotherapeutics

Virion is developing novel therapeutics for respiratory viral infections, focusing on influenza and respiratory syncytial virus. Founded on the research of Professors Nigel Dimmock and Andrew Easton at the University of Warwick, the company intends to develop the first broad-spectrum therapy for respiratory viral infections, potentially simplifying and accelerating treatment by removing the need for differential diagnosis.

LocationLondon, UK
CEOVanessa King
Partner Tim Haines